Daiichi & Esperion agreement for Bempedoic Acid
Daiichi Sankyo Europe has entered into a European licensing agreement with Esperion for bempedoic acid, and the bempedoic acid/ezetimibe combination tablet.
Read More
Tag: Esperion
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
